Contact:
4008465777
-
About Us
News & Events
-
02-22
Tonghua Dongbao: First Chinese-made dual-target inhibitor for gout (THDBH151 Tablets) meets primary endpoint in phase I clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase I pivotal ...
-
02-07
Tonghua Dongbao announces NMPA acceptance of clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) intended for weight loss indications
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...
-
01-17
Tonghua Dongbao: novel URAT1 inhibitor (THDBH130 Tablets) meets primary endpoint in phase IIa clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a multicenter, ran...
-
12-11
Tonghua Dongbao: Clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) approved
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) rec...
-
12-05
Tonghua Dongbao: Liraglutide injection approved for marketing
Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") recently received the Pharmaceutical Product Registration Certificate for liraglutide injection issued by National Medical...
-
11-01
Tonghua Dongbao: Net profit excluding non-recurring gains and losses attributable to shareholders of the parent company up 26.19% YoY in Q3 2023
On the evening of October 30, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") released its quarterly report for Q3 2023. In Q3 2023, the Company's revenue was R...